Building a differentiated and diversified portfolio of 15-20 companies

A portfolio of life science companies diversified across a range of therapeutic areas and different stages of the development cycle.

Portfolio in numbers*

£736m

Value of life sciences portfolio

11

High quality companies

9

clinical programmes

10 year targets

15-20

Sustainable portfolio of leading life science companies

2-3

New companies created every year

3-5

companies to approval; accessing the steepest part of the life science valuation curve

A differentiated and diversified portfolio

To deliver sustainable value we seek to build a portfolio of 15-20 companies, with each company built on a product-focused strategy. Over portfolio is diversified across therapeutic areas and different stages of the development cycle.

*Unless stated all numbers as of 31 December 2020 

Cell therapy is the introduction of selected, and sometimes engineered, cells into a patient, harnessing the power of a patient’s immune system to combat their disease. The therapy may have wide applications as a cancer treatment, with the potential for cure in some patients.

Cell therapy companies

Autolus

Autolus is a clinical-stage biopharmaceutical company focusing on the development of precisely targeted, controlled and highly active T effector cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care.

Cell type
CAR-T
Stage
Clinical

Unless stated all data at 31 December 2020

Achilles Therapeutics

Achilles Therapeutics is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell.

Cell type
TILs
Stage
Clinical

All data at 31 December 2020

Quell Therapeutics

Quell Therapeutics was founded with the aim of developing engineered T regulatory (Treg) cell therapies. Tregs are a subset of T cells with the potential to downregulate the immune system.

Cell type
T-Reg
Stage
Pre-clinical

Unless stated al data at 31 December 2020

Resolution Therapeutics

Resolution is developing macrophage cell therapies to repair inflammatory organ damage.

Cell type
Macrophage
Stage
Pre-clinical

All data at 31 December 2020

Neogene Therapeutics

Neogene is developing a process to manufacture a wholly personalised autologous product employing engineered neoantigen-specific T cells.

Cell type
TCR
Stage
Pre-clinical

All data at 31 December 2020

Gene therapy is the introduction of genetic material into cells to replace missing or defective genes. If a gene doesn’t function properly, the introduction of a normal copy of a gene may be able to treat or prevent disease. It is a technique that has the potential to deliver long-term and potentially curative benefits to patients with genetic disorders.

Gene therapy companies

Freeline Therapeutics

Freeline is a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases.

Target tissue compartment
Systemic
Stage
Clinical

Unless stated all data at 31 December 2020

Gyroscope Therapeutics

Gyroscope is developing gene therapy beyond rare disease to treat a leading cause of blindness, dry age-related macular degeneration (dry-AMD).

Target tissue compartment
Retinal
Stage
Clinical

All data at 31 December 2020

SwanBio Therapeutics

SwanBio Therapeutics is a gene therapy company developing leading-edge medicines to deliver dramatic clinical efficacy for the treatment of genetically defined neurological conditions.

Target tissue compartment
CNS
Stage
Pre-clinical

All data at 31 December 2020

Purespring Therapeutics

Purespring seeks to advance gene therapies for the treatment of chronic renal diseases that are currently poorly addressed with existing treatments.

Target tissue compartment
Renal
Stage
Pre-clinical

All data at 31 December 2020

Based on proteins which have a therapeutic effect. Biologics are complex, large molecule drugs

Biologics companies

Anaveon

Anaveon is a pre-clinical phase biopharmaceutical company that specialises in the development of treatments for diseases with immune system dysfunction.

Focus
Immune system dysfunction
Stage
Pre-clinical

Unless stated all data at 31 December 2020

A small molecule is a small, chemically manufactured compound with a low molecule weight. Small molecule drugs help regulate a biological target such as an enzyme, channel or receptor to modify a disease process.

Small molecule companies

OMass Therapeutics

OMass Therapeutics is an Oxford University spin-out backed by Syncona and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.

Focus
Native Mass Spectrometry
Stage
Drug discovery

All data at 31 December 2020

As we seek to build a diversified portfolio of 15-20 companies, some companies may not succeed and we may receive attractive offers for our companies from third parties.

Blue Earth

Blue Earth Diagnostics was founded to develop and commercialise molecular imaging agents, addressing areas of high unmet medical need.

Nightstar

Nightstar was a leading clinical-stage gene therapy company focused on developing and commercialising novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness.

14MG

14M Genomics was a cancer diagnostic business that was founded in partnership with the Wellcome Trust Sanger Institute in 2014.

Azeria Therapeutics

Azeria was a small molecule drug discovery company targeting treatment of oestrogen receptor positive breast cancer.